The change in thinking about the ways type 2 diabetes evolves indirectly opened the door to considering new ways of thinking about how type 1 diabetes behaves. That shift led to considering whether that door swung both ways and if type 1 diabetics might benefit from treatments designed to treat type 2 diabetes.
Category: Products & Tech
Medtronic has begun distribution of i-port Advance, the first device to combine an injection port and an inserter in one complete set. i-port Advance can be used for people on insulin injection therapy who want to administer insulin conveniently while eliminating the need to puncture the skin with each dose of medication. i-port Advance injection port is FDA approved...
The FDA has requested clinical trial data from the manufacturer of saxagliptin, Bristol-Myers Squibb and AstraZeneca, to investigate a possible association between use of the type 2 diabetes drug and heart failure.
The U.S. FDA has approved the expanded use of the Dexcom G4 Platinum Continuous Glucose Monitoring System for patients with diabetes ages 2 to 17…
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing…
It’s difficult to make the FDA’s new guidance on blood glucose test strips sound sexy, but I’m going to try. Imagine this situation: you’re sitting in front of a fire with your boyfriend/girlfriend/spouse/lover/partner, relaxing on some soft cushions or maybe a bearskin rug. The lights are low. Candles twinkle. Wine glasses are...
Novo Nordisk has announced the launch of NovoFine Plus, an ultra-thin, ultra-short universal pen needle that aims to make injections more comfortable for patients with diabetes.
I was particularly interested in the Enlite sensor, as I had used its predecessor, the Sof-sensor, for two years before switching to the Dexcom G4 sensor. For a long time, I complained at a high pitch about the Sof-sensor, and have found the Dexcom G4 to be worlds better.
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca and Bristol-Myers Squib new type 2 diabetes treatment, Farxiga (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
I have no doubt that HelpAround will benefit the diabetes community. Our lives depend on supplies, after all, but with our busy lifestyles and scattered minds, forgetting something is a real risk. As we begin to use HelpAround, other communities will learn and become inspired by the solidarity among people with diabetes.